MedTrace Logo

Biomarkers of P. Vivax Relapse

NCT04228315 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-01-14

No results posted yet for this study

Summary

Plasmodium vivax malaria is difficult to manage because even after taking medicine that kills the infection in the blood, it can continue to hide quietly in the liver, later re-emerging into the blood and causing another episode of malaria illness (relapse). This clinical trial aims to enroll patient with P. vivax infections and try to detect signals in blood, urine and/or saliva coming from the silent liver stages to help identify who could benefit from treatment with primaquine. It also will explore if certain factors of patients negatively impact primaquine efficacy.

Conditions

  • Malaria
  • Vivax Malaria
  • Relapse
  • CYP2D6 Polymorphism

Interventions

DRUG

Primaquine

radical cure dosing

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    collaborator OTHER

  • Armed Forces Research Institute of Medical Sciences, Thailand

    lead OTHER_GOV

Principal Investigators

  • Norman Waters, PhD · Armed Forces Research Institute of Medical Sciences, Thailand

  • Michele Spring, MD · Armed Forces Research Institute of Medical Sciences, Thailand

  • Ladaporn Bodhidatta, MD · Armed Forces Research Institute of Medical Sciences, Thailand

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-19
Primary Completion
2021-06-30
Completion
2024-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04228315 on ClinicalTrials.gov